Navigation Links
Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of Life Questionnaires All Play Prominent Roles
Date:8/27/2012

rminated Trial Analysis 495 Endpoints - Clinical Trials in Chronic Obstructive Pulmonary Disorder - Marketed and Pipeline Products Assessment 765.1 Introduction 765.2 Primary Endpoints Used in COPD Clinical Trials 805.2.1 Pulmonary Function Tests 805.2.2 Baseline Dyspnea Index and Borg-Dyspnea Score 805.2.3 Rate of Exacerbations 805.2.4 Induced Sputum Analysis 805.2.5 Biomarkers of COPD 805.3 Secondary Endpoints Used in COPD Clinical Trials 805.3.1 Exercise Endurance Time 805.3.2 Serum Hematology 805.3.3 Six Minute Walk Distance 805.3.4 Time to First Exacerbation 815.4 COPD Therapeutics – Major Marketed Drugs 815.4.1 Spiriva HandiHaler (Tiotropium Bromide Inhalation Powder) 815.4.2 Brovana (Arformoterol) 825.4.3 Foradil Aerolizer (Formoterol Fumarate Inhalation Powder) 835.4.4 Symbicort (Budesonide/Formoterol Fumarate Dihydrate) 845.4.5 Advair Diskus (Fluticasone Propionate and Salmeterol Inhalation Powder) 855.4.6 Daxas (roflumilast) 875.5 COPD Therapeutics – Promising Drugs Under Clinical Development 885.5.1 Aclidinium Bromide 885.5.2 NVA237 (Glycopyrronium Bromide) 895.5.3 Dulera 895.6 Phase III Clinical Trial Analysis 905.6.1 Completed Trial Analysis 905.6.2 Active Trials Analysis 945.6.3 Terminated Trial Analysis 985.7 Phase II Clinical Trial Analysis 1005.7.1 Completed Trial Analysis 1005.7.2 Active Trial Analysis 1045.7.3 Terminated Trial Analysis 1076 Endpoints - Clinical Trials in Cystic Fibrosis - Marketed and Pipeline Products Assessment 1256.1 Introduction 1256.2 Primary Endpoints Used in Cystic Fibrosis Clinical Trials 1296.2.1 Coefficient of Fat Absorption 1296.2.2 Lung Microbiology 1296.2.3 Biomarkers 1296.3 Secondary Endpoints Used in Cystic Fibrosis Clinical Trials 1296.3.1 Nasal Potential Difference 1296.3.2 Sweat Chloride Concentration 1296.4 Cystic Fibrosis Therapeutics – Major Marketed Drugs 1296.4.1 Tobi (Tobramycin Inhalation Solution) 1296.4.2 Pulmozyme (Dornase Alfa) 1306.4.3 Cayston (aztreonam for Inhalation Solution) 1316
'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
2. As Tuberculosis Grows More Difficult to Control, Vaccine Candidate to Prevent Disease Enters Clinical Testing
3. Millennium Laboratories Announces Landmark Pharmacogenetics Clinical Outcomes Study
4. VolitionRX to Begin Prospective Clinical Trial in Colon Cancer
5. Indegene Introduces TrialPedia 2.0 with Advantage Insights, Making It the Most Comprehensive Clinical Trial Analytics and Decision Support Platform for the Pharma Industry
6. Imprimis Pharmaceuticals Signs Agreement With DPT Labs For Clinical Supplies In Advance Of Planned Phase 3 Studies For Its Ketoprofen-Based Topical Anti-Inflammatory Drug
7. AbGenomics International Obtains FDA Agreement on Its Phase 2 Clinical Trial Plans
8. Nectid Announces Initiation Of Clinical Development Of Autism And Pain Drugs
9. Meritage Pharma Initiates Clinical Trial of Oral Budesonide Suspension for Adolescent and Adult Patients with Eosinophilic Esophagitis
10. MultiCell Technologies Updates Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer in vitro Models
11. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015  Following a bipartisan vote ... moved H.R. 284, the Medicare DMEPOS Competitive Bidding ... for Homecare (AAHomecare) released a statement praising the ... pass the legislation. "Today,s mark-up of ... Ways and Means Committee is a critical step ...
(Date:2/27/2015)... HOUSTON, TX , Feb. 27, 2015 /PRNewswire/ ... and Bloom Burton & Co. Ltd. ("Bloom Burton") today ... (the "Lock-Up") 2,353,130 common shares of the Company ("Common ... to the Lock-Up. Of the Common Shares released from ... upon release from the Lock-Up while the remainder will ...
(Date:2/27/2015)... 2015   Synageva BioPharma Corp. (Synageva) ... developing therapeutic products for rare diseases, joins the ... Organisation for Rare Diseases™ (EURORDIS™), The Global Genes ... Rare Disease Day. On the last ... and other participants conduct special events to raise ...
Breaking Medicine Technology:Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... Inc. (Nasdaq:GILD) today announced that Study 103, ... once-daily,anti-HIV drug Viread(R) (tenofovir disoproxil fumarate or ... for chronic hepatitis B virus,(HBV) infection, met ... Viread is non-inferior to the company's once-daily ...
... study demonstrates 75% of patients receiving highest ... June 25, 2007 /PRNewswire-FirstCall/ -- According to,findings ... of the,American Diabetes Association (ADA) in Chicago, ... dose of human,GLP-1 analog under development by ...
Cached Medicine Technology:Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 2Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 3Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target 4
(Date:2/28/2015)... My Shiney Hiney® LLC., the renowned brand ... Las Vegas, Nevada for the annual ASD Market Week tradeshow. ... leading consumer-goods tradeshows and My Shiney Hiney will be one ... Shiney Hiney can be found at booth number C1663. , ... at-home personal hygiene brush and cleansing system exclusively created to ...
(Date:2/27/2015)... 27, 2015 OnChip Devices , ... introduced miniature, wire bondable, silicon ESD (Electrostatic Discharge) protection ... The ESD88NP and ESD88PN ... sensitive LED and IC products. These Zeners exhibit ... All devices meet the requirements of IEC61000 and ...
(Date:2/27/2015)... 2015 Today, February 27th, is "Shine A ... along with LXR Organics and Living Fuel, ... to raise awareness and promote prevention, rescue and restoration for ... the END IT Coalition, slavery is the 2nd largest global ... in 167 countries around the world. Slavery includes bonded labor, ...
(Date:2/27/2015)... Altec Products, Inc., announced today that ADSS ... Management Partner of the Year. ADSS Global provides Sage ... complimentary solutions for their customers across the world. Altec ... to provide clients with paperless solutions that integrate seamlessly ... thrilled to recognize ADSS Global for their expertise in ...
(Date:2/27/2015)... Calif. (PRWEB) February 27, 2015 ... who are documented to use Medicaid, the federal ... families, according to a new study from UC ... the greatest predictor of farmworker use of Medicaid, ... care regardless of documentation status, was having children. ...
Breaking Medicine News(10 mins):Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3Health News:KAJ Brothers Join the Campaign to 'End It - Shine A Light On Slavery' 2Health News:Altec Announces 2014 Sage ERP Document Management Partner of the Year Award Recipient 2Health News:UC Davis Study Finds Undocumented Farmworkers Use Medicaid Half as Often as Documented Farmworkers 2Health News:UC Davis Study Finds Undocumented Farmworkers Use Medicaid Half as Often as Documented Farmworkers 3
... Discusses key issues ... ... only on motivating employees, but also on how supportive companies are of the program, according ... High-Engagement Wellness Program , scheduled for Thursday, April 22 at 3:00 pm EST, Fiona Gathright, ...
... Medication offers hope for treatment with fewer side effects, experts ... reporting that a drug is showing promise in early testing ... and potentially deadly liver ailment. , It,s too early to ... years before it,s ready to seek federal approval to be ...
... discovery 15 years ago that the genes BRCA1 and ... was a breakthrough for cancer prediction and therapy, especially ... Alfons Meindl (Klinikum rechts der Isar of the Technische ... the U.K., and the U.S., can identify another gene ...
... Dr. ... of skin care products that claim to be "natural" or "organic" have cancer-causing ingredients. ... New York, NY (PRWEB) April ... recent study: a number of skin care products that claim to be "natural" or "organic" ...
... ... that allows unlimited penetration testing against your environment to help achieve compliance, such as ... , ... 21, 2010 -- Clone Systems, Inc. has introduced Clone Guard® CG-PenTest, a web portal ...
... D.C. (April 21, 2010)Past randomized clinical trials have ... can reduce the risk of colon cancer and ... Chase Cancer Center have found that an investigational ... can block one of the earliest molecular changes ...
Cached Medicine News:Health News:DSM Personalized Nutrition Webinar Examines Ways to Build Engagement in Wellness Programs 2Health News:DSM Personalized Nutrition Webinar Examines Ways to Build Engagement in Wellness Programs 3Health News:In Early Test, New Hepatitis C Drug Shows Promise 2Health News:Researchers identify a new breast and ovarian cancer susceptibility gene 2Health News:Carcinogen Found in Many "Natural" Skin Care Products, One Skin Care Specialist Fights Back 2Health News:Clone Systems, Inc. Introduces On-Demand Penetration Testing Service 2Health News:Researchers show that nitric oxide-donating naproxen can boost colorectal cancer prevention 2
... CDI creates a smoother fit in the ... patient. The padded continuous hook and eye ... and the extra strong, yet very thin ... as a reinforced open crotch, gripper lace ...
This compression garment can be used immediatlely following Abdominoplasty, Tram Flap, Abdominal Liposuction, Lipoplasty, Suction Lipectomy, Stomach Liposuction, Liposculpture and Tummy Tuck procedur...
This compression garment can be used immediatlely following Abdominoplasty, Tram Flap, Abdominal Liposuction, Lipoplasty, Suction Lipectomy, Stomach Liposuction, Liposculpture and Tummy Tuck procedur...
Short Girdle, Mid-thigh, Front Closure...
Medicine Products: